Immune complexes in ovarian cancer.
Immune complexes have been assayed in ovarian cancer with a polyethylene-glycol (P.E.G.) precipitation assay and a Clq solid-phase assay. Significantly higher levels of immune complexes were detected in patients in relapse compared with those in remission. Remission values were within the range obtained for a control group. Evidence was produced that immune-complex levels rise before the clinical detection of relapse, and it is suggested that the P.E.G. assay could be a useful marker of disease progress.
D000912:Antibodies, Neoplasm / Q000302:isolation & purification; D000936:Antigen-Antibody Complex; D000951:Antigens, Neoplasm; D002291:Carcinoma, Papillary / Q000276:immunology*; D005260:Female; D006801:Humans; D007105:Immune Complex Diseases; D007074:Immunoglobulin G / Q000302:isolation & purification; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000276:immunology; D010051:Ovarian Neoplasms / Q000276:immunology*; D011379:Prognosis; D012075:Remission, Spontaneous
D000912:Antibodies, Neoplasm; D000936:Antigen-Antibody Complex; D000951:Antigens, Neoplasm; D007074:Immunoglobulin G